Get started
Author

Aroog Khaliq

The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
2024 · Aroog Khaliq, William Wesson, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients
2024 · Raeef Rahman, Anas Zayad, et al. · Current Oncology · 2
PDF
Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients
2024 · Dania Shoaib, Aroog Khaliq, et al. · Blood · 1
Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma
2024 · Mehak M Laharwal, Jordan Snyder, et al. · Blood · 1
Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
2024 · Mohammad Ahsen Soomro, Shebli Atrash, et al. · Transplantation and Cellular Therapy · 1
Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Current Oncology
Impact of Early Bloodstream Infections on Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
2026 · Moazzam Shahzad, Muhammad Kashif Amin, et al. · Transplantation and Cellular Therapy
PDF
POSTER: MPN-696: Persistent Infectious and Thrombotic Comortality in Myeloproliferative Neoplasm–Associated Deaths: A National Multiple-Cause-of-Death Analysis (2003–2024)
2026 · Mohammad Ahsen Soomro, Amy Varghese, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: HL-988: From Lymphoma Mortality to Survivorship Mortality: Changing Underlying Causes of Death Among Hodgkin Lymphoma–Associated Decedents, 2003–2024
2026 · Aroog Khaliq, Zafar Aleem Suchal, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-1690: Restrictive vs Liberal Red Blood Cell Transfusion Strategies in Critically Ill Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: An Emulated Target Trial Across Two Independent Databases
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-1508: Extramedullary Disease and Prolonged Hematotoxicity After Real-World Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Evidence Synthesis
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-936: Chronification of Follicular Lymphoma Mortality: A 22-Year National Multiple-Cause-of-Death Analysis, 2003–2024
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-936: Chronification of Follicular Lymphoma Mortality: A 22-Year National Multiple-Cause-of-Death Analysis, 2003–2024
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Clinical Lymphoma Myeloma & Leukemia
MCL-932: Targeted Therapy Era and the Reclassification of Mantle Cell Lymphoma From Underlying to Contributing Cause of Death: A 22-Year National Multiple-Cause-of-Death Analysis
2026 · Mohammad Ahsen Soomro, Zafar Aleem Suchal, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-970: Early Acute Kidney Injury and Mortality in Critically Ill Patients With Multiple Myeloma: A Two-Cohort Study
2026 · Zafar Aleem Suchal, Mohammad Ahsen Soomro, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1508: Extramedullary Disease and Prolonged Hematotoxicity After Real-World Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Evidence Synthesis
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-696: Persistent Infectious and Thrombotic Comortality in Myeloproliferative Neoplasm–Associated Deaths: A National Multiple-Cause-of-Death Analysis (2003–2024)
2026 · Mohammad Ahsen Soomro, Amy Varghese, et al. · Clinical Lymphoma Myeloma & Leukemia
HL-988: From Lymphoma Mortality to Survivorship Mortality: Changing Underlying Causes of Death Among Hodgkin Lymphoma–Associated Decedents, 2003–2024
2026 · Aroog Khaliq, Zafar Aleem Suchal, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-1690: Restrictive vs Liberal Red Blood Cell Transfusion Strategies in Critically Ill Patients With Acute: Myeloid Leukemia and Myelodysplastic Syndromes: An Emulated Target Trial Across Two Independent
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MCL-932: Targeted Therapy Era and the Reclassification of Mantle Cell Lymphoma From Underlying to Contributing Cause of Death: A 22-Year National Multiple-Cause-of-Death Analysis
2026 · Mohammad Ahsen Soomro, Zafar Aleem Suchal, et al. · Clinical Lymphoma Myeloma & Leukemia
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
2026 · Moazzam Shahzad, Aroog Khaliq, et al. · Transplantation and Cellular Therapy
Outcomes of Patients Who Develop Bacteremia in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
2026 · Moazzam Shahzad, Shah Rukh, et al. · Transplantation and Cellular Therapy
Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis
2025 · Moazzam Shahzad, Shah Rukh, et al. · Blood
Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis
2025 · Moazzam Shahzad, Aqeeb Ur Rehman, et al. · Blood
PDF
Outcomes of Newly Diagnosed Myeloma Patients with Double-Hit and Single High-Risk Cytogenetics Receiving Autologous Stem Cell Transplant (ASCT)
2025 · Raeef Labib Rahman, Aroog Khaliq, et al. · Transplantation and Cellular Therapy
Works count: 30
Citation count: 8
H-index: 2
I10-index:
Year
Topic
Type